The DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Non-classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency revisited: an update with a special focus on adolescent and adult women
Abstract
BACKGROUND: Non-classic congenital hyperplasia (NCAH) due to 21-hydroxylase deficiency is a common autosomal recessive disorder characterized by androgen excess. OBJECTIVE AND RATIONALE: We conducted a systematic review and critical assessment of the available evidence pertaining to the epidemiology, pathophysiology, diagnosis and management of NCAH. A meta-analysis of epidemiological data was also performed. SEARCH METHODS: Peer-reviewed studies evaluating NCAH published up to October 2016 were reviewed. Multiple databases were searched including MEDLINE, EMBASE, Cochrane, ERIC, EBSCO, dissertation abstracts, and current contents. OUTCOMES: The worldwide prevalence of NCAH amongst women presenting with signs and symptoms of androgen excess is 4.2% (95% confidence interval: 3.2-5.4%). The clinical consequences of NCAH expand from infancy, i.e. accelerated growth, to adolescence and adulthood, i.e. premature pubarche, cutaneous symptoms and oligo-ovulation in a polycystic ovary syndrome (PCOS)-like clinical picture. The diagnosis of NCAH relies on serum 17-hydroxyprogesterone (17-OHP) concentrations. A basal 17-OHP concentration ≥2 ng/ml (6 nmol/l) should be used for screening if more appropriate in-house cut-off values are not available. Definitive diagnosis requires a 17-OHP concentration ≥10 ng/ml (30 nmol/l), either basally or after cosyntropin-stimulation. Molecular genetic analysis of the CYP21A2 gene, which is responsible for 21-hydroxylase activity, may be used for confirmation purposes and should be offered to all patients with NCAH along with genetic counseling because these patients frequently carry alleles that may result in classic CAH, the more severe form of the disease, in their progeny. Treatment must be individualized. Glucocorticoid replacement therapy may benefit pediatric patients with accelerated growth or advanced bone age or adult women seeking fertility, whereas adequate control of menstrual irregularity, hirsutism and other cutaneous symptoms is best served by the use of oral contraceptive pills and/or anti-androgens. Some women may need ovulation induction or assisted reproductive technology to achieve pregnancy. Patients with NCAH have a higher risk of miscarriage and may benefit from glucocorticoid treatment during pregnancy. WIDER IMPLICATIONS: Evidence-based diagnostic and treatment strategies are essential for the proper management of women with NCAH, especially considering that these patients may need different therapeutic strategies at different stages during their follow-up and that appropriate genetic counseling may prevent the occurrence of CAH in their children.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Funnel plots for detecting bias in meta-analysis
Sterne, J. A. C., & Egger, M. (2001) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(01)00377-8 · Cited by 3,779
Azziz, R., Carmina, E., Dewailly, D., Diamanti-Kandarakis, E., Escobar-Morreale, H. F., Futterweit, W., Janssen, O. E., Legro, R. S., Norman, R. J., Taylor, A. E., et al. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0178 · Cited by 2,143
Self-citationAzziz, R., Carmina, E., Dewailly, D., Diamanti-Kandarakis, E., Escobar-Morreale, H. F., Futterweit, W., Janssen, O. E., Legro, R. S., Norman, R. J., Taylor, A. E., et al. (2009) · Fertility and Sterility · doi:10.1016/j.fertnstert.2008.06.035 · Cited by 2,132 · cited 11×
“This review is exclusively focused on NCAH and represents the integrated view of a special expert committee appointed by the Androgen Excess & PCOS (AE-PCOS) Society, Inc., with expertise in diverse fields including pediatric, adult and reproductive endocrinology.”
InfluentialSelf-citationSpeiser, P. W., Azziz, R., Baskin, L. S., Ghizzoni, L., Hensle, T. W., Merke, D. P., Meyer-Bahlburg, H. F. L., Miller, W. L., Montori, V. M., Oberfield, S. E., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2631 · Cited by 1,468 · cited 2×
“Overall, while some NCAH patients may be at risk for short stature, this risk appears to be relatively small and most children reach a relatively normal final height for family standards (Speiser et al., 2010) (Level of evidence: B).”
Self-citationAndrogen Excess in Women: Experience with Over 1000 Consecutive Patients
Azziz, R., Sanchez, L. A., Knochenhauer, E. S., Moran, C., Lazenby, J., Stephens, K. C., Taylor, K., & Boots, L. R. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031122 · Cited by 1,132
Self-citationWild, R. A., Carmina, E., Diamanti-Kandarakis, E., Dokras, A., Escobar-Morreale, H. F., Futterweit, W., Lobo, R., Norman, R. J., Talbott, E., & Dumesic, D. A. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2724 · Cited by 1,010 · cited 11×
“This review is exclusively focused on NCAH and represents the integrated view of a special expert committee appointed by the Androgen Excess & PCOS (AE-PCOS) Society, Inc., with expertise in diverse fields including pediatric, adult and reproductive endocrinology.”
InfluentialSelf-citationGlucocorticoids, prenatal stress and the programming of disease
Harris, A., & Seckl, J. (2011) · Hormones and Behavior · doi:10.1016/j.yhbeh.2010.06.007 · Cited by 871
Genotyping steroid 21-hydroxylase deficiency: hormonal reference data
NEW, M. I., LORENZEN, F., LERNER, A. J., KOHN, B., OBERFIELD, S. E., POLLACK, M. S., DUPONT, B., STONER, E., LEVY, D. J., PANG, S., et al. (1983) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-57-2-320 · Cited by 624
Self-citationEscobar-Morreale, H. F., Carmina, E., Dewailly, D., Gambineri, A., Kelestimur, F., Moghetti, P., Pugeat, M., Qiao, J., Wijeyaratne, C. N., Witchel, S. F., et al. (2012) · Human Reproduction Update · doi:10.1093/humupd/dmr042 · Cited by 494 · cited 2×
“…adrenal androgen excess could be treated either by suppressing ACTH production with glucocorticoids and therefore lowering the excessive androgen production by the adrenal glands or by blocking the effects of androgens on their receptors with anti-androgens (Escobar-Morreale et al., 2012).”
Self-citationAbdominal adiposity and the polycystic ovary syndrome
Escobar-Morreale, H. F., & Millán, J. L. S. (2007) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2007.07.003 · Cited by 386
Self-citationNew, M. I., Abraham, M., Gonzalez, B., Dumic, M., Razzaghy-Azar, M., Chitayat, D., Sun, L., Zaidi, M., Wilson, R. C., & Yuen, T. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1300057110 · Cited by 365
The backdoor pathway to dihydrotestosterone
Auchus, R. J. (2004) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2004.09.004 · Cited by 347
Nonclassical 21-Hydroxylase Deficiency
New, M. I. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1645 · Cited by 315
Tusie-Luna, M. T., Traktman, P., & White, P. C. (1990) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)45304-x · Cited by 254
Azziz, R., Hincapie, L. A., Knochenhauer, E. S., Dewailly, D., Fox, L., & Boots, L. R. (1999) · Fertility and Sterility · doi:10.1016/s0015-0282(99)00383-0 · Cited by 244
Self-citationAdvances in the meta-analysis of heterogeneous clinical trials II: The quality effects model
Doi, S. A. R., Barendregt, J. J., Khan, S., Thalib, L., & Williams, G. M. (2015) · Contemporary Clinical Trials · doi:10.1016/j.cct.2015.05.010 · Cited by 227
Adrenal incidentaloma and patients with homozygous or heterozygous congenital adrenal hyperplasia.
Jaresch, S., Kornely, E., Kley, H. K., & Schlaghecke, R. (1992) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.74.3.1311000 · Cited by 227 · cited 1×
“Accordingly, patients with adenomas identified incidentally should be first evaluated for NCAH/CAH before any attempt of surgical treatment (Jaresch et al., 1992).”
Late-onset adrenal hyperplasia in hirsutism
Kuttenn, F., Couillin, P., Girard, F., Billaud, L., Vincens, M., Boucekkine, C., Thalabard, J.-C., Maudelonde, T., Spritzer, P., Mowszowicz, I., et al. (1985) · New England Journal of Medicine · doi:10.1056/nejm198507253130404 · Cited by 213
Speiser, P. W., New, M. I., & White, P. C. (1988) · New England Journal of Medicine · doi:10.1056/nejm198807073190104 · Cited by 205
Late-onset steroid 21-hydroxylase deficiency: a variant of classical congenital adrenal hyperplasia
KOHN, B., LEVINE, L. S., POLLACK, M. S., PANG, S., LORENZEN, F., LEVY, D., LERNER, A. J., RONDANINI, G. F., DUPONT, B., & NEW, M. I. (1982) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-55-5-817 · Cited by 204
Falhammar, H., Frisén, L., Hirschberg, A. L., Norrby, C., Almqvist, C., Nordenskjöld, A., & Nordenström, A. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-2093 · Cited by 204
Fertility in women with nonclassical congenital adrenal hyperplasia due to 21-hydroxylase deficiency
Bidet, M., Bellanné-Chantelot, C., Galand-Portier, M.-B., Golmard, J.-L., Tardy, V., Morel, Y., Clauin, S., Coussieu, C., Boudou, P., Mowzowicz, I., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1383 · Cited by 204 · cited 4×
“Bidet et al. (2010) observed that the risk of miscarriage in the absence of glucocorticoid treatment was significantly higher than with treatment (odds ratio: 4.5, 95% confidence interval: 1.4–14.2).”
InfluentialIncreased mortality in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency
Falhammar, H., Frisén, L., Norrby, C., Hirschberg, A. L., Almqvist, C., Nordenskjöld, A., & Nordenström, A. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-2957 · Cited by 196 · cited 2×
“A review of the literature identified only a few cases of adults with NCAH who suffered acute adrenal insufficiency (Young et al., 2010; Falhammar et al., 2014; Reichman et al., 2014).”
Kamrath, C., Hochberg, Z., Hartmann, M. F., Remer, T., & Wudy, S. A. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-1997 · Cited by 191
Moran, C., Azziz, R., Carmina, E., Dewailly, D., Fruzzetti, F., Ibañez, L., Knochenhauer, E. S., Marcondes, J. A. M., Mendonca, B. B., Pignatelli, D., et al. (2000) · American Journal of Obstetrics and Gynecology · doi:10.1067/mob.2000.108020 · Cited by 185
Self-citationVölkl, T. M. K., Simm, D., Beier, C., & Dörr, H. G. (2006) · PEDIATRICS · doi:10.1542/peds.2005-1005 · Cited by 184
Tusie-Luna, M.-T., Speiser, P. W., Dumic, M., New, M. I., & White, P. C. (1991) · Molecular Endocrinology · doi:10.1210/mend-5-5-685 · Cited by 183
Reproductive outcome of women with 21-hydroxylase-deficient nonclassic adrenal hyperplasia
Moran, C., Azziz, R., Weintrob, N., Witchel, S. F., Rohmer, V., Dewailly, D., Marcondes, J. A. M., Pugeat, M., Speiser, P. W., Pignatelli, D., et al. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0062 · Cited by 174 · cited 5×
“Fertility and reproductive outcome in women with NCAH Despite the adrenal and ovarian androgen excess, the majority of women with NCAH will conceive spontaneously (Feldman et al., 1992; Moran et al., 2006) (Level of evidence: B).”
InfluentialSelf-citationStikkelbroeck, N. M. M. L., Hoefsloot, L. H., de Wijs, I. J., Otten, B. J., Hermus, A. R. M. M., & Sistermans, E. A. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021681 · Cited by 171
Falhammar, H., Nyström, H. F., Ekström, U., Granberg, S., Wedell, A., & Thorén, M. (2012) · European Journal of Endocrinology · doi:10.1530/eje-11-0828 · Cited by 170
Mallappa, A., Sinaii, N., Kumar, P., Whitaker, M. J., Daley, L.-A., Digweed, D., Eckland, D. J. A., Van Ryzin, C., Nieman, L. K., Arlt, W., et al. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-3809 · Cited by 167 · cited 1×
“Most recently evaluated is Chronocort®, a modified release formulation of hydrocortisone (Mallappa et al., 2015).”
CHROUSOS, G. P., LORIAUX, D. L., MANN, D. L., & CUTLER, G. B. (1982) · Annals of Internal Medicine · doi:10.7326/0003-4819-96-2-143 · Cited by 158 · cited 1×
“In fact, while a few patients present with increased ACTH and have the same pathophysiological mechanisms of CAH (Chrousos et al., 1982), in the majority of the affected subjects with NCAH, ACTH production is normal (Azziz et al., 1994).”
Clinical and Biological Phenotypes in Late-Onset 21 Hydroxylase Deficiency
DEWAILLY, D., VANTYGHEM-HAUDIQUET, M.-C., SAINSARD, C., BUVAT, J., CAPPOEN, J. P., ARDAENS, K., RACADOT, A., LEFEBVRE, J., & FOSSATI, P. (1986) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-63-2-418 · Cited by 151
Self-citationCyproterone Acetate Versus Hydrocortisone Treatment in Late-Onset Adrenal Hyperplasia
SPRITZER, P., BILLAUD, L., THALABARD, J.-C., BIRMAN, P., MOWSZOWICZ, I., RAUX-DEMAY, M.-C., CLAIR, F., KUTTENN, F., & MAUVAIS-JARVIS, P. (1990) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-70-3-642 · Cited by 146
Insulin insensitivity in adrenal hyperplasia due to nonclassical steroid 21-hydroxylase deficiency.
Speiser, P. W., Serrat, J., New, M. I., & Gertner, J. M. (1992) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.75.6.1464643 · Cited by 143
CYP11B1 Mutations Causing Non-Classic Adrenal Hyperplasia due to 11 -Hydroxylase Deficiency
Joehrer, K., Geley, S., Strasser-Wozak, E. M. C., Azziz, R., Wollmann, H. A., Schmitt, K., Kofler, R., & White, P. C. (1997) · Human Molecular Genetics · doi:10.1093/hmg/6.11.1829 · Cited by 142 · cited 1×
“In contrast, NCAH due to mutations of CYP11B1 and HSD3B2 are extremely rare (Azziz et al., 1991; Joehrer et al., 1997; Lutfallah et al., 2002; Moran et al., 1999).”
Self-citationArmengaud, J.-B., Charkaluk, M.-L., Trivin, C., Tardy, V., Bréart, G., Brauner, R., & Chalumeau, M. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-0314 · Cited by 135
Pall, M., Azziz, R., Beires, J., & Pignatelli, D. (2010) · Fertility and Sterility · doi:10.1016/j.fertnstert.2009.06.025 · Cited by 123
Self-citationHelmberg, A., Tusie-Luna, M. T., Tabarelli, M., Kofler, R., & White, P. C. (1992) · Molecular Endocrinology · doi:10.1210/mend.6.8.1406709 · Cited by 123
Adrenal Androgens and Androgen Precursors-Definition, Synthesis, Regulation and Physiologic Actions
Turcu, A., Smith, J. M., Auchus, R., & Rainey, W. E. (2014) · Comprehensive physiology · doi:10.1002/cphy.c140006 · Cited by 113 · cited 1×
“Finally, 3α-hydroxysteroid dehydrogenase can oxidize androstanediol to DHT in target tissues (Kamrath et al., 2012; Turcu et al., 2014) (Level of evidence: B).”
CHETKOWSKI, R. J., DEFAZIO, J., SHAMONKI, I., JUDD, H. L., & CHANG, R. J. (1984) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-58-4-595 · Cited by 108
Pinto, G., Tardy, V., Trivin, C., Thalassinos, C., Lortat-Jacob, S., Nihoul-Fékété, C., Morel, Y., & Brauner, R. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021433 · Cited by 101
Marino, R., Ramirez, P., Galeano, J., Perez Garrido, N., Rocco, C., Ciaccio, M., Warman, D. M., Guercio, G., Chaler, E., Maceiras, M., et al. (2011) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2011.04123.x · Cited by 98
Nella, A. A., Mallappa, A., Perritt, A. F., Gounden, V., Kumar, P., Sinaii, N., Daley, L.-A., Ling, A., Liu, C.-Y., Soldin, S. J., et al. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-1916 · Cited by 91
Pro-453 to Ser mutation in CYP21 is associated with nonclassic steroid 21-hydroxylase deficiency
Owerbach, D., Sherman, L., Ballard, A. L., & Azziz, R. (1992) · Molecular Endocrinology · doi:10.1210/mend.6.8.1406699 · Cited by 91
Self-citationSpeiser, P. W., Knochenhauer, E. S., Dewailly, D., Fruzzetti, F., Marcondes, J. A. M., & Azziz, R. (2000) · Molecular Genetics and Metabolism · doi:10.1006/mgme.2000.3036 · Cited by 89
Self-citationParajes, S., Quinteiro, C., Domínguez, F., & Loidi, L. (2008) · PLoS ONE · doi:10.1371/journal.pone.0002138 · Cited by 87
Junction Site Analysis of Chimeric CYP21A1P/CYP21A2 Genes in 21-Hydroxylase Deficiency
Chen, W., Xu, Z., Sullivan, A., Finkielstain, G. P., Van Ryzin, C., Merke, D. P., & McDonnell, N. B. (2012) · Clinical Chemistry · doi:10.1373/clinchem.2011.174037 · Cited by 86
Steroid 21-hydroxylase (P450c21): a new allele and spread of mutations through the pseudogene
Wedell, A., & Luthman, H. (1993) · Human Genetics · doi:10.1007/bf00218263 · Cited by 81
Nandagopal, R., Sinaii, N., Avila, N. A., Van Ryzin, C., Chen, W., Finkielstain, G. P., Mehta, S. P., McDonnell, N. B., & Merke, D. P. (2011) · European Journal of Endocrinology · doi:10.1530/eje-11-0019 · Cited by 81 · cited 4×
“%) parents were found to have genotype analyses diagnostic for NCAH (Nandagopal et al., 2011).”
InfluentialProfiles of 21-Carbon Steroids in 21-Hydroxylase Deficiency
Turcu, A. F., Rege, J., Chomic, R., Liu, J., Nishimoto, H. K., Else, T., Moraitis, A. G., Palapattu, G. S., Rainey, W. E., & Auchus, R. J. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-1023 · Cited by 77
Tardy, V., Menassa, R., Sulmont, V., Lienhardt-Roussie, A., Lecointre, C., Brauner, R., David, M., & Morel, Y. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1202 · Cited by 73
Araújo, R. S., Mendonca, B. B., Barbosa, A. S., Lin, C. J., Marcondes, J. A. M., Billerbeck, A. E. C., & Bachega, T. A. S. S. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-2163 · Cited by 70
Barbat, B., Bogyo, A., Raux-Demay, M.-C., Kuttenn, F., Boué, J., Simon-Bouy, B., Serre, J.-L., Boué, A., & Mornet, E. (1995) · Human Mutation · doi:10.1002/humu.1380050205 · Cited by 68
Sex-dimorphic effects of prenatal treatment with dexamethasone
Wallensteen, L., Zimmermann, M., Thomsen Sandberg, M., Gezelius, A., Nordenström, A., Hirvikoski, T., & Lajic, S. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-1543 · Cited by 67 · cited 1×
“Of note, the selection of glucocorticoid is important since dexamethasone crosses the fetoplacental barrier and may have a long-term detrimental impact on fetal intellectual development (Harris and Seckl, 2011; Wallensteen et al., 2016) (Level of evidence: D).”
Falhammar, H., & Torpy, D. J. (2016) · Endocrine Practice · doi:10.4158/ep151085.ra · Cited by 63 · cited 2×
“The excessive ACTH stimulation also determines the hypertrophy of fasciculata and reticularis zones, leading to adrenal hyperplasia and to adrenocortical nodularity in some cases (Falhammar and Torpy, 2016) (Level of evidence: A).”
11β-Hydroxylase deficiency in hyperandrogenism
Azziz, R., Boots, L. R., Parker, C. R., Bradley, E., & Zacur, H. A. (1991) · Fertility and Sterility · doi:10.1016/s0015-0282(16)54239-3 · Cited by 61
Self-citationLoidi, L., Quinteiro, C., Parajes, S., Barreiro, J., Lestón, D. G., Cabezas‐Agrícola, J. M., Sueiro, A. M., Araujo‐Vilar, D., Catro‐Feijóo, L., Costas, J., et al. (2006) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2006.02465.x · Cited by 55
Non-classic congenital adrenal hyperplasia
Witchel, S. F. (2013) · Steroids · doi:10.1016/j.steroids.2013.04.010 · Cited by 52
Self-citationEzquieta, B., Cueva, E., Varela, J., Oliver, A., Fernández, J., & Jariego, C. (2002) · Acta Paediatrica · doi:10.1080/080352502760148595 · Cited by 47
Infertility and Reproductive Function in Patients with Congenital Adrenal Hyperplasia
Lekarev, O., Lin-Su, K., & Vogiatzi, M. G. (2015) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2015.07.009 · Cited by 38 · cited 1×
“Anovulation is the main cause of subfertility in NCAH women, which is most evident by the positive outcome in response to ovulation induction (Reichman et al., 2014; Lekarev et al., 2015).”
Stoupa, A., González-Briceño, L., Pinto, G., Samara-Boustani, D., Thalassinos, C., Flechtner, I., Beltrand, J., Bidet, M., Simon, A., Piketty, M., et al. (2015) · Hormone Research in Paediatrics · doi:10.1159/000369901 · Cited by 37 · cited 2×
“Risk of adrenal insufficiency As previously reported, there is limited evidence that some patients with NCAH who present with reduced cortisol response to ACTH need glucocorticoid supplementation when undergoing major surgery or if trauma occurs (Stoupa et al., 2015).”
Pallan, P. S., Lei, L., Wang, C., Waterman, M. R., Guengerich, F. P., & Egli, M. (2015) · Molecular Endocrinology · doi:10.1210/me.2015-1127 · Cited by 19 · cited 1×
“Using computational analyses, mutations associated with classic CAH have been found to disrupt essential enzyme functions such as membrane anchoring or substrate binding (Pallan et al., 2015).”
Bleicken, C., Loidi, L., Dhir, V., Parajes, S., Quinteiro, C., Dominguez, F., Grötzinger, J., Sippell, W. G., Riepe, F. G., Arlt, W., et al. (2009) · Human Mutation · doi:10.1002/humu.20926 · Cited by 15
Cited by
Polycystic Ovary Syndrome: Definition, Aetiology, Diagnosis and Treatment
Escobar-Morreale, H. F. (2018) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2018.24 · Cited by 2,083
Self-citationCongenital Adrenal Hyperplasia—Current Insights in Pathophysiology, Diagnostics, and Management
Claahsen - van der Grinten, H. L., Speiser, P. W., Ahmed, S. F., Arlt, W., Auchus, R. J., Falhammar, H., Flück, C. E., Guasti, L., Huebner, A., Kortmann, B. B. M., et al. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnab016 · Cited by 556
Martin, K. A., Chang, R. J., Ehrmann, D. A., Ibanez, L., Lobo, R. A., Rosenfield, R. L., Shapiro, J., Montori, V. M., & Swiglo, B. A. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-2437 · Cited by 512
Ibáñez, L., Oberfield, S. E., Witchel, S., Auchus, R. J., Chang, R. J., Codner, E., Dabadghao, P., Darendeliler, F., Elbarbary, N. S., Gambineri, A., et al. (2017) · Hormone Research in Paediatrics · doi:10.1159/000479371 · Cited by 463
Self-citationMartin, K. A., Anderson, R. R., Chang, R. J., Ehrmann, D. A., Lobo, R. A., Murad, M. H., Pugeat, M. M., & Rosenfield, R. L. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-00241 · Cited by 339
Metadata
- Authors
- Carmina, E., Dewailly, D., Escobar-Morreale, H. F., Kelestimur, F., Moran, C., Oberfield, S., Witchel, S. F., & Azziz, R.
- Venue
- Human Reproduction Update
- Publisher
- Oxford University Press (OUP)
- Published
- 2017-06-05
- Volume
- 23
- Issue
- 5
- Pages
- 580-599
- ISSN
- 1355-4786 (ISSN-L)
- 1460-2369
- OpenAlex
- W2623213129
- Cited by
- 201
- References
- 64
- FWCI
- 5.63
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.